Endovascular stent grafts market seen reaching $7.13B by 2030

The endovascular stent grafts market is projected to climb from $1.99 billion in 2026 to $7.13 billion by 2030, driven by rising vascular disease, more minimally invasive procedures and new graft designs. North America led the market in 2025 as demand builds for less invasive treatment of aneurysms and other vessel conditions.

Why it matters: - Endovascular stent grafts are gaining traction because hospitals and patients want less invasive treatment options for vascular disease. - The market outlook points to rapid expansion as aortic aneurysm, dissection and other cardiovascular cases increase worldwide. - The category matters for care delivery because these devices can reduce recovery time and procedural risk compared with conventional surgery.

What happened: - The Business Research Company projected the global endovascular stent grafts market will rise from $1.45 billion in 2025 to $1.99 billion in 2026. - The same report forecasts the market will reach $7.13 billion by 2030. - The report puts the 2025-2026 growth rate at 37.9% and the 2026-2030 CAGR at 37.5%. - North America led the market in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

The details: - Endovascular stent grafts are metallic mesh stents covered with a fabric graft. - Clinicians insert the devices through a catheter, often via the groin or arm arteries. - The devices treat aneurysms and vessel stenosis by reinforcing weakened vessel walls. - The report cites rising vascular disease rates, early adoption of coronary and peripheral grafts and greater awareness of aortic aneurysm treatment options as growth drivers. - It also points to ongoing stent graft design improvements and broader adoption of hybrid vascular grafts. - The report says customized stent grafts, biologic and hybrid graft materials, more thoracic and abdominal aortic repair procedures, and tighter safety and regulatory standards are shaping the forecast period. - The report also said its 2026 market editions include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - A free sample report is available here. - The full report is available here.

Between the lines: - The growth forecast suggests a market moving from niche device use toward broader clinical adoption. - The mix of minimally invasive demand and stricter safety expectations could favor companies that can combine durability, customization and regulatory readiness. - The cited acute coronary event data from Australia underscores the size of the broader cardiovascular treatment burden supporting demand for vascular interventions.

What's next: - The report expects continued growth in minimally invasive surgeries worldwide. - More hybrid vascular graft adoption and cardiovascular infrastructure expansion are likely to support market momentum. - Device makers will likely keep focusing on customized designs and biologic materials as procedure volumes rise. - Healthcare systems will face growing pressure to expand access to endovascular repair for aortic disease.